Literature DB >> 18456302

Genetically destined potentials for N-linked glycosylation of influenza virus hemagglutinin.

Manabu Igarashi1, Kimihito Ito, Hiroshi Kida, Ayato Takada.   

Abstract

The addition of oligosaccharide side chains to influenza virus hemagglutinin (HA) is believed to facilitate viral escape from immune pressure in the human population. To determine the implicit potentials for acquisition of N-linked glycosylation, we analyzed the genetic background of 16 subtypes of avian influenza virus, some of which may be potential pandemic viruses in the future. We found a significant difference among HA subtypes in their genomic sequences to produce N-glycosylation sites. Notably, recently circulating avian influenza viruses of the H5 and H9 subtypes may have rather greater capacities to undergo mutations associated with glycosylation of HA than past pandemic viruses. We hypothesize that influenza viruses maintained in natural reservoirs could have different potentials for sustained circulation, depending on their HA subtypes, if introduced into the human population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456302     DOI: 10.1016/j.virol.2008.03.036

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

1.  Genetic characterization of swine influenza viruses (H3N2) isolated from Minnesota in 2006-2007.

Authors:  Sandeep R P Kumar; Laure Deflube; Moanaro Biswas; Raghunath Shobana; Subbiah Elankumaran
Journal:  Virus Genes       Date:  2011-05-21       Impact factor: 2.332

2.  Molecular analysis of influenza A H1N1pdm09 virus circulating in Madhya Pradesh, India in the year 2017.

Authors:  Salonee Pandey; Mahima Sahu; Varsha Potdar; Pradip Barde
Journal:  Virusdisease       Date:  2018-07-16

3.  Evidence for N-glycan shielding of antigenic sites during evolution of human influenza A virus hemagglutinin.

Authors:  Yuki Kobayashi; Yoshiyuki Suzuki
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

Review 4.  A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  J Mol Biol       Date:  2017-06-23       Impact factor: 5.469

5.  Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin.

Authors:  Manabu Igarashi; Kimihito Ito; Reiko Yoshida; Daisuke Tomabechi; Hiroshi Kida; Ayato Takada
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

Review 6.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

7.  Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses.

Authors:  Rafael A Medina; Silke Stertz; Balaji Manicassamy; Petra Zimmermann; Xiangjie Sun; Randy A Albrecht; Hanni Uusi-Kerttula; Osvaldo Zagordi; Robert B Belshe; Sharon E Frey; Terrence M Tumpey; Adolfo García-Sastre
Journal:  Sci Transl Med       Date:  2013-05-29       Impact factor: 17.956

8.  Use of host-like peptide motifs in viral proteins is a prevalent strategy in host-virus interactions.

Authors:  Tzachi Hagai; Ariel Azia; M Madan Babu; Raul Andino
Journal:  Cell Rep       Date:  2014-05-29       Impact factor: 9.423

9.  Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors.

Authors:  Akila Jayaraman; Xiaoying Koh; Jing Li; Rahul Raman; Karthik Viswanathan; Zachary Shriver; Ram Sasisekharan
Journal:  Biochem J       Date:  2012-06-15       Impact factor: 3.857

10.  Protein clustering and RNA phylogenetic reconstruction of the influenza A [corrected] virus NS1 protein allow an update in classification and identification of motif conservation.

Authors:  Edgar E Sevilla-Reyes; David A Chavaro-Pérez; Elvira Piten-Isidro; Luis H Gutiérrez-González; Teresa Santos-Mendoza
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.